Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

8 Continuous vs 8 Intermittent Cycles in First and Second Line Treatment of Patients With HER2/Neu Negative, Incurable, Metastatic or Unresectable Locally Advanced Breast Cancer.

NCT01935492 is registered in ClinicalTrials.gov with Borstkanker Onderzoek Groep as lead sponsor.

NCT NCT01935492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01935492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
8 Continuous vs 8 Intermittent Cycles in First and Second Line Treatment of Patients With HER2/Neu Negative, Incurable, Metastatic or Unresectable Locally Advanced Breast Cancer.
Lead sponsor
Borstkanker Onderzoek Groep
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2010
Completion date
April 1, 2019
Enrollment
420 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human epidermal growth factor 2 negative carcinoma of breast, metastatic breast cancer